OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
SA Melander, A Kayed, KV Andreassen… - European Journal of …, 2024 - Elsevier
Objective Dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonists are
therapeutic agents with an interesting liver-specific mode of action suitable for metabolic …
therapeutic agents with an interesting liver-specific mode of action suitable for metabolic …
[HTML][HTML] Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine …
E Berta, S Halmi, I Molnár, D Hutkai, S Csiha… - …, 2024 - pmc.ncbi.nlm.nih.gov
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid
and glucose metabolism exerting protection against atherosclerosis by multiple actions on …
and glucose metabolism exerting protection against atherosclerosis by multiple actions on …
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
A Kayed, S Melander, K Andreassen, M Karsdal… - 2021 - researchsquare.com
Obesity-related metabolic disorders, including non-alcoholic fatty liver disease and its more
progressive form non-alcoholic steatohepatitis, are causing an increased health burden …
progressive form non-alcoholic steatohepatitis, are causing an increased health burden …